EUCTR2005-002844-24-BE进行中（未招募）1 期
An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension - LVGX
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- For purposes of study entry, clinical worsening is defined as WHO functional class deterioration and documentation of clinical worsening. The following subjects will be eligible to enter the extension trial.
- •The subject discontinues the placebo-controlled study (LVGY) due to clinical worsening and is on placebo, tadalafil 2.5 mg, 10 mg, or 20 mg.
- •The subject completes Week 16 in the placebo-controlled study (LVGY), and has one of the following:
- •.No clinical worsening.
- •.Clinical worsening at the Week 16 visit and is receiving placebo, tadalafil 2.5
- •mg, 10 mg, or 20 mg.
- •- A female subject of childbearing potential must have a negative urine pregnancy test at the screening visit and agree to use two medically reliable methods of contraception (e.g., barrier with spermacide or hormonal contraception) until study completion.
- •- Written informed consent (and written assent for minors) will be obtained prior to any study procedure being performed.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Are nursing or pregnant.
- •- Have left-sided heart disease, including any of the following:
- •clinically significant aortic or mitral valve disease (i.e., aortic stenosis, aortic insufficiency, mitral stenosis, moderate or greater mitral regurgitation); pericardial constriction; restrictive or congestive cardiomyopathy; left ventricular ejection fraction < 40% by multigated radionucleotide angiogram (MUGA), angiography, or echocardiography; left ventricular shortening fraction < 22% by echocardiography; life-threatening cardiac arrhythmias; symptomatic coronary artery disease within 5 years of study entry.
- •- Have a systolic blood pressure < 90 mm Hg or diastolic blood pressure < 50 mm Hg at screening.
- •- Have a history of angina pectoris or other condition that was treated with long-or short-acting nitrates within 12 weeks before administration of study drug.
- •- Have a musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease besides pulmonary arterial hypertension that may significantly limit ambulation.
- •- Current treatment with antiretroviral therapy (protease inhibitor), sustemic ketoconazole, or systemic itraconazole.
- •- Current treatment with a prostacyclin or analogue, L-arginine, phosphodiesterase inhibitor other than tadalafil, or investigational drug. An exception is allowed in Japan for subjects who participated in placebo-controlled study LVGY while receiving treatment with beraprost sodium.
- •- Are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •- Are employed by Lilly or ICOS (that is, employees, temporary contract workers, or designees responsible for the conduct of the study). Immediate family of Lilly or ICOS employees may participate in Lilly sponsored clinical trials, but are not permitted to participate at a Lilly or ICOS facility. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
研究者
相似试验
进行中（未招募）
不适用
An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension - LVGXEUCTR2005-002844-24-DEEli Lilly and Company350
尚未招募
3 期
To evaluate the long-term safety of Rusfertide in patients with polycythemia veraCTRI/2024/03/063705Protagonist Therapeutics
进行中（未招募）
1 期
ong-term Follow-up Study of Male Adults with Hemophilia B Previously Treated with Etranacogene Dezaparvovec (CSL222)MedDRA version: 20.0Level: LLTClassification code: 10018939Term: Haemophilia B (Factor IX) Class: 10010331Hemophilia BCTIS2023-503765-37-00CSL Behring LLC56
已完成
3 期
An Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn*s Disease10017969Crohn syndromeregional enteritisNL-OMON54703Galapagos NV15
进行中（未招募）
1 期
Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated PaiModerate to Severe Endometriosis Associated PainMedDRA version: 16.1Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 100000004872EUCTR2013-001047-31-ITAbbVie Deutschland GmbH & Co. KG495